Synermedics links legacy systems into HIS ASP
Synermedics links legacy systems into HIS ASPSynermedics, an HIS application service provider in Norcross, GA, has licensed multiple gateways from Healthcare.com, an integration software and services company based in Marietta, GA. The Cloverleaf
Synermedics links legacy systems into HIS ASP
Synermedics, an HIS application service provider in Norcross, GA, has licensed multiple gateways from Healthcare.com, an integration software and services company based in Marietta, GA. The Cloverleaf Gateways will enable Synermedics to integrate disparate applications by linking a hospitals legacy systems to PortalMed, Synermedics Internet portal, to provide both content and connectivity to its healthcare customers.
The thin-client architecture of PortalMed allows users to access hosted applications through a standard Internet browser with a PC or other low-cost digital device. The Cloverleaf integration engine is designed to create a messaging platform that supports both asynchronous and synchronous links to a range of programs, databases, objects, and protocols.
- Search Again
- Return To HNN Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
